Abstract
Heart failure is a common and growing public health problem, with increasing incidence and prevalence over the last 2 decades. Despite improvements in its current management, heart failure is still associated with significant morbidity and mortality. This has motivated the search for newer therapeutic modalities, which are based on a better understanding on the pathophysiologic events that lead to heart failure. This review summarizes the potential role of new pharmacological agents in the treatment of heart failure. These potential new agents can be classified according to their role in the modulation of the main pathophysiologic abnormalities that characterized heart failure, that include: cellular-extracellular abnormalities, endothelial dysfunction, neurohormonal and immunologic activation.
| Original language | Spanish |
|---|---|
| Pages (from-to) | 624-634 |
| Number of pages | 11 |
| Journal | Revista Espanola de Cardiologia |
| Volume | 54 |
| Issue number | 5 |
| State | Published - May 1 2001 |
| Externally published | Yes |
Fingerprint
Keywords
- Heart failure
- New pharmacological agents
- Pathophysiology
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Nuevos farmacos en insuficiencia cardíaca. / Lopera, Gustavo; Castellanos, Agustin; De Marchena, Eduardo.
In: Revista Espanola de Cardiologia, Vol. 54, No. 5, 01.05.2001, p. 624-634.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nuevos farmacos en insuficiencia cardíaca
AU - Lopera, Gustavo
AU - Castellanos, Agustin
AU - De Marchena, Eduardo
PY - 2001/5/1
Y1 - 2001/5/1
N2 - Heart failure is a common and growing public health problem, with increasing incidence and prevalence over the last 2 decades. Despite improvements in its current management, heart failure is still associated with significant morbidity and mortality. This has motivated the search for newer therapeutic modalities, which are based on a better understanding on the pathophysiologic events that lead to heart failure. This review summarizes the potential role of new pharmacological agents in the treatment of heart failure. These potential new agents can be classified according to their role in the modulation of the main pathophysiologic abnormalities that characterized heart failure, that include: cellular-extracellular abnormalities, endothelial dysfunction, neurohormonal and immunologic activation.
AB - Heart failure is a common and growing public health problem, with increasing incidence and prevalence over the last 2 decades. Despite improvements in its current management, heart failure is still associated with significant morbidity and mortality. This has motivated the search for newer therapeutic modalities, which are based on a better understanding on the pathophysiologic events that lead to heart failure. This review summarizes the potential role of new pharmacological agents in the treatment of heart failure. These potential new agents can be classified according to their role in the modulation of the main pathophysiologic abnormalities that characterized heart failure, that include: cellular-extracellular abnormalities, endothelial dysfunction, neurohormonal and immunologic activation.
KW - Heart failure
KW - New pharmacological agents
KW - Pathophysiology
UR - http://www.scopus.com/inward/record.url?scp=0343772997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0343772997&partnerID=8YFLogxK
M3 - Article
C2 - 11412754
AN - SCOPUS:0343772997
VL - 54
SP - 624
EP - 634
JO - Revista Espanola de Cardiologia
JF - Revista Espanola de Cardiologia
SN - 0300-8932
IS - 5
ER -